[ET Net News Agency, 30 July 2019] CSPC Pharmaceutical Group Limited (01093) said
SYHA1807 developed by the group was granted approval by the National Medical Products
Administration of the People's Republic of China to conduct clinical trials in China.
The product has a number of patent applications in China and overseas. It is a new type
of small-molecule kinase inhibitor and currently there is no product of the same type
available in the global market. The clinical indication approved is for the treatment of
small-cell lung cancer. (RC)